AIKI Aikido Pharma Inc

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology

Company profile

Ticker

AIKI

Exchange

NASDAQ

Website

www.aikido.com

CEO

Anthony C. Hayes

Incorporated in

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Health Technology > Biotechnology

Industry (SEC)

Services - Commercial Physical & Biological Research

PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Medpace • Incyte • Exelixis • ICON • Precigen ...

Former names

Biospherics Inc, Spherix Inc

SEC CIK

0000012239

Corporate docs

Articles of Incorporation & Bylaws

IRS number

520849320

AIKI stock data

S&P 500

1M 1Y 2Y 5Y

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

14 May 20

7 Jul 20

31 Dec 20

News

Company financial data Financial data

Chart AIKI financial data

Quarter (USD)	Mar 20	Dec 19	Sep 19	Jun 19
Revenue
Net income	-8.33M	973K	-3.36M	-644K
Diluted EPS	-0.91		-1.38	-0.3
Operating income	-2.4M	-3.18M	-902K	-888K
Net change in cash	161K	-222K	-251K	118K
Cash on hand	252K	91K	313K	564K

Annual (USD)	Dec 19	Dec 18	Dec 17	Dec 16
Revenue	9K	28K	1.24M	877K
Net income	-4.18M	1.73M	-3.31M	-6.48M
Diluted EPS	-1.67	0.91	-0.6	6.51
Net profit margin	-46478%	6168%	-267%	-738%
Operating income	-5.69M	-6.87M	-3.82M	-8.55M
Net change in cash	69K	-178K	100K	0
Cash on hand	91K	22K	200K	100K
Cost of revenue	9K	28K

Financial data from company earnings reports

Recent insider trades

AIKI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	10b5-1	$Price	#Shares	$Value	#Remaining
8 Nov 19	Aikido Pharma	Common Stock	Other	Dispose J	No	0	9,226	0	1,636,230
28 Oct 19	Aikido Pharma	Common Stock	Other	Dispose J	No	0	90,258	0	1,645,456
28 Feb 19	Aikido Pharma	Common Stock	Buy	Aquire P	No	199998	35,714	7.14B	1,735,714
30 Jun 17	Aikido Pharma	Common Stock	Buy	Aquire P	No	675000	1,700,000	1.15T	1,700,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2020

AIKI institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	1	9	-88.9%
Opened positions	0	2	EXIT
Closed positions	8	1	+700.0%
Increased positions	0	3	EXIT
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	119K	EXIT
Total shares	0	90.71K	EXIT
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Proequities	0	$0

Largest transactions	Shares	Bought/sold	Change
Renaissance Technologies	0	-60.17K	EXIT
Vanguard	0	-20.74K	EXIT
UBS UBS	0	-6.49K	EXIT
DB Deutsche Bank	0	-2.27K	EXIT
BAC Bank of America	0	-538	EXIT
Victory Capital Management	0	-445	EXIT
BLK BlackRock	0	-56	EXIT
MS Morgan Stanley	0	-1	EXIT
Proequities	0	0

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Quest Patent Research • Inventergy Global • Endeavor Ip

Management Discussion

The Company experienced very little or no revenue in the last two years and we don’t expect any revenue until a biotechnology product is fully developed which may not occur for many years.
For the year ended December 31, 2019 and 2018, we incurred a loss from operations of $5.7 million and $6.9 million, respectively. The decrease in net loss in the 2019 period was primarily attributed to $1.4 million decrease in amortization of patent portfolio, $2.2 million decrease in impairment of intangible assets, $0.2 million decrease in selling, general and administrative expense, and partially offset by $2.5 million increase in research and development expense related with license acquisition.
For the year ended December 31, 2019 and 2018, other expense (income) was approximately $1.5 million and $8.6 million, respectively. The decrease of other income was primarily attributed to a $6.8 million decrease in change in fair value of investments and a $0.7 million decrease in the fair value of warrant liabilities, and partially offset by $0.3 million decrease in other expenses. During the year ended December 31, 2019, we recorded a loss of $0.9 million related to our investment in DatChat and a $2.4 million unrealized loss on our investment in Hoth as the closing stock price Hoth increased from a cost basis of $5.42 to $6.19 as of December 31, 2019.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abandon, abuse, academic, accurately, addressing, adequacy, adequate, adequately, Affordability, Affordable, AIKI, aikido, Alexander, allocation, altogether, antiviral, aspect, asserted, assessment, assist, attain, attract, Baltimore, billing, block, brand, bring, broad, broaden, broader, broadly, Bulletin, burden, candidate, capability, capable, care, cease, cell, certainty, cessation, challenged, challenging, charged, chemotherapeutic, chemotherapy, choose, civil, clearance, cleared, closure, coding, combat, compete, competing, competition, competitive, complementary, compliance, complicating, comply, compound, concentrated, concentration, conclusion, confidence, confidentiality, consecutive, constantly, constrain, contamination, convenience, convenient, convince, copyright, costly, country, coverage, create, created, criminal, criteria, critical, curtail, curtailment, damage, data, death, decide, defend, deficiency, defraud, degree, delisted, delisting, demand, demonstrate, demonstrated, deny, denying, desirable, desire, desired, detection, difficult, direct, discovering, discovery, discretion, discretionary, disease, dissolve, distract, divert, documented, drop, Drs, duration, ease, educate, education, educational, effectuate, efficacy, effort, eligibility, eligible, enhance, enhanced, enroll, enrolled, enrollment, entity, entry, enumerated, eventual, eventually, evolve, evolving, exclusive, exclusivity, expansion, expend, experienced, expertise, explanatory, expose, exposed, exposure, expressed, extent, extraordinary, face, faced, false, FDA, FDCA, fewer, field, fluctuation, forced, forego, foregoing, foreseeable, found, fraud, fraudulent, frequently, Frieman, fully, fund, funding, gemcitabine, global, globally, goal, good, grow, growing, growth, halt, harm, harmed, healthcare, heavily, high, higher, highly, hire, hope, human, immunotherapy, impede, impose, imposed, impossible, inability, inadequate, incidental, inconclusive, increasingly, IND, independent, independently, induce, ineffective, Influenza, infrastructure, inherent, inherently, inhibit, inhibitory, injury, institutional, insufficient, insurance, intensely, internationally, introduce, introduction, invalidate, invalidated, invalidity, investigation, invite, IRB, issuer, jeopardize, justify, key, knowingly, labeling, larger, launching, leave, leaving, led, legislation, legislative, length, lengthy, letter, light, line, list, listing, locate, lose, low, lung, MacKerell, magnitude, maintenance, managerial, mandatory, manner, manufacture, manufacturing, Marburg, Marketplace, Maryland, Matthew, media, Medicaid, medical, Medicare, merit, minimal, minimum, misappropriation, mitigate, MMA, Modernization, modestly, modification, monetary, monitor, monitoring, mouse, multiple, narrow, necessitated, negotiate, newly, noncompliance, notification, notwithstanding, oncology, opportunity, OTC, OTCQX, outbreak, outsource, overcome, pace, pandemic, paragraph, party, patient, payer, permanent, personnel, perspective, Pharma, pharmacoeconomic, physician, pioneering, pipe, pipeline, placement, point, policy, poolable, population, Portability, pose, potent, practice, preclinical, predetermined, predict, predicted, predictive, preempted, premarket, prescribe, pressure, prevalence, prevalent, primary, product, profile, profitability, profitable, profitably, program, projected, promise, promotional, promptly, properly, proprietary, prosecute, prosecuted, prosecution, prospective, prostate, protect, protecting, protection, protective, protocol, prove, proximity, publicly, quality, quantity, question, quotation, radiation, ranged, rapidly, reach, reaching, readily, recall, receipt, recommend, Reconciliation, recovery, recruiting, reduction, referral, reform, regain, regional, registration, reimbursed, reimbursement, reliable, reluctant, rely, remuneration, renowned, reoccurrence, repeal, repealed, replicate, replication, reputation, resistance, resource, response, return, revoked, routine, royalty, Rule, safe, safer, safety, sample, satisfaction, satisfactorily, schedule, scheme, scrutiny, seasoned, secret, sentiment, shelter, shorten, showed, side, simply, site, situation, slower, small, soliciting, sought, sound, SOX, specialty, specific, specifically, spectrum, speculation, spend, spending, Sponsored, spread, steady, stockat, Street, strength, strictly, stringent, strong, structured, Stuart, study, substitution, superior, superiority, supplement, supply, susceptible, suspend, sweeping, team, technical, test, testing, therapeutic, therapy, therefrom, thinly, timeline, tolerated, toll, toxicity, trademark, transgenic, transmission, transparency, travel, treat, treating, trend, trial, tumor, turn, UMB, unacceptable, uncertain, understand, undesirable, unenforceability, unexpected, unfavorable, unknown, unmet, unpredictable, unprofitable, unproven, untested, USPTO, vaccine, variable, vary, varying, viable, viral, voluntary, VStock, Wall, Watson, withdrawal, worldwide

Removed: abroad, absence, account, adjusted, adjustment, advisory, affiliate, agreeable, amendment, amortization, amounted, analyzed, ancillary, APA, approach, arising, ASC, assumption, back, beneficially, BioLexa, breach, brought, Buyer, campaign, categorized, Chelexa, classifying, closed, Codification, committed, compensation, complexity, comprised, comprising, consent, consideration, constituting, contemplated, content, converted, covenant, customary, deferral, deposit, derivative, deviation, disbursed, discontinued, discussed, Distinguishing, dual, Eastern, effected, embedded, enforced, enjoin, enjoining, equal, escrow, estimation, exchanged, existence, expanding, expiration, expressly, financed, firm, fostering, fractional, free, full, fundamental, Hedging, historically, illegal, implied, import, incurable, infringed, initiation, instrument, interruption, involved, IP, IPO, isolation, iv, lessee, liable, logarithmic, mandatorily, maturity, maximize, maximum, meeting, Mellow, methodology, momentum, month, mutual, mutually, navigating, noncontrolling, nonemployee, nonpublic, nonvoting, obligation, October, perception, permissible, preclude, principle, professional, prohibiting, promulgated, quantitative, ratio, Realization, realizing, recently, recognition, redeemable, Replacement, representation, Reserve, restraining, retain, round, rounded, satisfied, scientist, segregated, senior, September, serve, settlement, shifted, source, stake, strategically, strike, sublicense, subsequently, substance, surviving, thereof, Topic, transferred, twelve, uncertificated, vi, waived, waiver, warranty, written

From filing 10-Q 2020 Q1